Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...

Driven by a surging pipeline, the MASH therapeutic landscape is radically transforming as more drugs reach clinical trials. While Madrigal's Rezdiffra marked a groundbreaking first approval, it also ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Thomas J. Brock is a CFA and CPA with more ...

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, ...